Company / Cost of Revenue
ImmunityBio, Inc. Cost of Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$753.0K
FY2025
5-year range
$0 / $753.0K
FY2022-FY2025
Trend
-
vs FY2024
Sector context
#80 of 85
Health Care
What the data says
Among 85 Health Care companies, ImmunityBio, Inc. is in the top 6% for cost of revenue. Increased from $0 to $753,000 over the past 2 years.
Based on SEC 10-K filings.
$753,000 in FY2025.
Increased from $0 to $753,000 over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 85This company $753.0K Sector average $2.0B
▼
-100.0% below sector average
Key checks
Key Insights
- Ranks #80 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $753.0K | - |
| FY2024 | $0 | - |
| FY2023 | $0 | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026